JP2002539805A5 - - Google Patents

Download PDF

Info

Publication number
JP2002539805A5
JP2002539805A5 JP2000607471A JP2000607471A JP2002539805A5 JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5 JP 2000607471 A JP2000607471 A JP 2000607471A JP 2000607471 A JP2000607471 A JP 2000607471A JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5
Authority
JP
Japan
Prior art keywords
cells
cell
dendritic
tumor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000607471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539805A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008472 external-priority patent/WO2000057705A1/en
Publication of JP2002539805A publication Critical patent/JP2002539805A/ja
Publication of JP2002539805A5 publication Critical patent/JP2002539805A5/ja
Pending legal-status Critical Current

Links

JP2000607471A 1999-03-31 2000-03-30 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的t細胞のインビトロ産生 Pending JP2002539805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28267999A 1999-03-31 1999-03-31
US09/282,679 1999-03-31
PCT/US2000/008472 WO2000057705A1 (en) 1999-03-31 2000-03-30 In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens

Publications (2)

Publication Number Publication Date
JP2002539805A JP2002539805A (ja) 2002-11-26
JP2002539805A5 true JP2002539805A5 (https=) 2007-06-07

Family

ID=23082644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000607471A Pending JP2002539805A (ja) 1999-03-31 2000-03-30 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的t細胞のインビトロ産生

Country Status (6)

Country Link
EP (1) EP1168924A4 (https=)
JP (1) JP2002539805A (https=)
CN (1) CN1353575A (https=)
AU (1) AU4183100A (https=)
CA (1) CA2367590A1 (https=)
WO (1) WO2000057705A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
DE69839215T2 (de) 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
EP1226235A2 (de) * 1999-10-22 2002-07-31 LESKOVAR, Peter Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
JP5054875B2 (ja) * 2000-02-11 2012-10-24 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 樹状細胞ハイブリッドによって活性化される細胞傷害性tリンパ球
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
DE10164819A1 (de) * 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
DE102010037622B4 (de) 2010-09-17 2012-07-12 Lophius Biosciences Gmbh Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CN102827826B (zh) * 2012-09-11 2017-07-04 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
CN108076642A (zh) 2015-05-08 2018-05-25 威尔逊沃夫制造公司 改进的用于测试的培养方法和装置
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー,インク. 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634750T2 (de) * 1995-03-31 2006-02-23 Université Libre de Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids

Similar Documents

Publication Publication Date Title
JP2002539805A5 (https=)
Cranmer et al. Clinical applications of dendritic cell vaccination in the treatment of cancer
JP4662776B2 (ja) 抗原負荷した樹状細胞ワクチンを前駆体から発生させる迅速ワンステップ法
Heemskerk et al. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells
JP2002539805A (ja) 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的t細胞のインビトロ産生
WO2012137538A1 (ja) 細胞傷害性t細胞誘導用組成物
US20180078627A1 (en) Method for antigen loading of dendritic cells and vaccine
JP6602377B2 (ja) 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途
Mason et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma
US20030082163A1 (en) Fused cells, methods of forming same, and therapies utilizing same
EP4015625A1 (en) Universal car-t cell and preparation and use thereof
CN116063449A (zh) 一种制备肿瘤抗原特异性t细胞的方法
US20250122473A1 (en) Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
Nair et al. RNA-transfected dendritic cells
JP2002500872A5 (https=)
EP1178822B1 (en) Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells
US20050170503A1 (en) In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
Plautz et al. Considerations on clinical use of T cell immunotherapy for cancer
Fairchild Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?
NZ508936A (en) Method for preparation and in vivo administration of antigen presenting cell composition
WO2022061811A1 (zh) 药物组合物及其制备方法和应用
US20100291683A1 (en) Modified Antigen Presenting Cells and Methods of Use
CN118221773B (zh) 与HLA相关的CMV pp65表位疫苗组合物与应用
WO1998021314A2 (en) Method of promoting b-cell proliferation and activation and of modulating the immune system
CN111166876A (zh) 一种免疫增强剂组合和编码核酸及其应用